BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29633562)

  • 21. How far are we from viral hepatitis elimination service coverage targets?
    Hutin YJ; Bulterys M; Hirnschall GO
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25050. PubMed ID: 29633520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research gaps in viral hepatitis.
    Boyd A; Duchesne L; Lacombe K
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25054. PubMed ID: 29633564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake.
    Grogan L; Tiernan M; Geogeghan N; Smyth B; Keenan E
    Ir J Med Sci; 2005; 174(2):14-20. PubMed ID: 16094907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi.
    Nyirenda M; Beadsworth MB; Stephany P; Hart CA; Hart IJ; Munthali C; Beeching NJ; Zijlstra EE
    J Infect; 2008 Jul; 57(1):72-7. PubMed ID: 18555534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B and hepatitis C virus infections: risk factors among drug users in Northwest England.
    Lamden KH; Kennedy N; Beeching NJ; Lowe D; Morrison CL; Mallinson H; Mutton KJ; Syed Q
    J Infect; 1998 Nov; 37(3):260-9. PubMed ID: 9892530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region.
    Baggaley RF; Nazareth J; Divall P; Pan D; Martin CA; Volik M; Seguy NS; Yedilbayev A; Reinap M; Vovc E; Mozalevskis A; Dadu A; Waagensen E; Kruja K; Sy TR; Nellums L; Pareek M
    J Travel Med; 2023 Feb; 30(1):. PubMed ID: 36426801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020.
    Dunn R; Musabaev E; Razavi H; Sadirova S; Bakieva S; Razavi-Shearer K; Brigida K; Kamili S; Averhoff F; Nasrullah M
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(34):1161-1165. PubMed ID: 32853186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infection with human immunodeficiency virus and hepatitis viruses in Chinese drug addicts.
    Baozhang T; Kaining Z; Jinxing K; Ruchang X; Ming L; Caixia Z; Li T
    Epidemiol Infect; 1997 Dec; 119(3):343-7. PubMed ID: 9440438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data.
    Palayew A; Stumo SR; Cooke GS; Hutchinson SJ; Jauffret-Roustide M; Maticic M; Harris M; Metwally AM; Razavi H; Lazarus JV;
    PLoS One; 2020; 15(7):e0235715. PubMed ID: 32722701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global reporting of progress towards elimination of hepatitis B and hepatitis C.
    Cui F; Blach S; Manzengo Mingiedi C; Gonzalez MA; Sabry Alaama A; Mozalevskis A; Séguy N; Rewari BB; Chan PL; Le LV; Doherty M; Luhmann N; Easterbrook P; Dirac M; de Martel C; Nayagam S; Hallett TB; Vickerman P; Razavi H; Lesi O; Low-Beer D
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):332-342. PubMed ID: 36764320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings.
    Easterbrook P; Sands A; Harmanci H
    Semin Liver Dis; 2012 May; 32(2):147-57. PubMed ID: 22760654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database.
    Zhou J; Dore GJ; Zhang F; Lim PL; Chen YM;
    J Gastroenterol Hepatol; 2007 Sep; 22(9):1510-8. PubMed ID: 17645479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.
    Alaama AS; Khattabi H; Mugisa B; Atta H; Hermez J; Hutin YJ
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):862-870. PubMed ID: 35817075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
    Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
    Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis B and C surveillance and screening programmes in the non-EU/EEA Member States of the WHO European Region: survey findings from 10 countries, 2012.
    Mozalevskis A; Eramova I; Safreed-Harmon K; Lazarus JV
    Euro Surveill; 2016 Jun; 21(22):. PubMed ID: 27277421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014).
    Lazarus JV; Mozalevskis A; Safreed-Harmon K; Eramova I
    Hepatol Med Policy; 2016; 1():3. PubMed ID: 30288307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Seroprevalence of hepatitis B and C viruses and risk factors in HIV infected children at the Felgehiwot referral hospital, Ethiopia.
    Abera B; Zenebe Y; Mulu W; Kibret M; Kahsu G
    BMC Res Notes; 2014 Nov; 7():838. PubMed ID: 25421947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of antibodies against hepatitis C virus and hepatitis B coinfection in healthy population in Bulgaria. A seroepidemiological study.
    Atanasova MV; Haydouchka IA; Zlatev SP; Stoilova YD; Iliev YT; Mateva NG
    Minerva Gastroenterol Dietol; 2004 Mar; 50(1):89-96. PubMed ID: 15719010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.